Drugs
4
in active trials · 8 in all
Trials
8 active
17 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
EGFR inhibitor |
Phase 3 | 1 Dec 2027Phase 2 trial completes | |||
| Next date | 1 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | NSCLC, EGFR Activating Mutation and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Nov 2026soonPhase 1/2 trial completes | |||
| Next date | Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Locally Advanced or Metastatic Solid Tumors, HR-positive, HER2-negative Advanced Breast Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jan 2028Phase 1/2 trial completes | |||
| Next date | Jan 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor Malignancies, Malignant Mesothelioma (MM) | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Metastatic Castration-resistant Prostate Cancer (mCRPC) | ||||
| Open drug page | |||||
About
- No active trial
- Rifampicin, TY-1091, TY-2136b, TY-2699a
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021